Jackson Center, PA, March 21, 2023 – Halberd Corporation (OTC PINK:HALB), leading up to the scheduled meeting with the Centers for Disease Control (CDC) on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E. coli samples previously provided by the CDC. Using Halberd’s patented extracorporeal ...
Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in-vitro Jackson Center, PA, February 21, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under ten minutes. Halberd’s patented extracorporeal process and patent-pending ...
Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing Jackson Center, PA, February 8, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria ...
Halberd’s method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains. Jackson Center, PA December 6, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication ...
Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states. The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes. This ...
Jackson Center, PA, March 8, 2022 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. Chester R. Cooper has joined its technical team. Dr. Cooper currently holds the position of Professor, Department of Biological Sciences, at Youngstown State University. Dr. Cooper has been a valuable resource in Halberd’s work at ...
A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer’s Disease/PTSD/CTE Jackson Center, PA, July 28, 2021 – Halberd Corporation (OTC-PINK: "HALB") establishes “proof of concept” taking a major step towards the elimination of multiple infectious diseases, such as, malaria, tuberculosis, sepsis, meningitis, and pandemics, among others, by successfully eliminating ...
Jackson Center, PA, June 9, 2021 – Halberd Corporation (OTC-PINK: "HALB") commences experimentations to eradicate three of the principal components of Alzheimer’s Disease. By eliminating these three critical antigens, which form the basis for neurofibrillary tangles in the brain, Halberd believes that its patented extracorporeal treatment process can slow or stop the progress of the ...
Breakthrough Achievement Enables Extracorporeal Eradication of Pathogens Via Radio Frequency Waves and/or Laser Emissive Energy Jackson Center, PA, May 25, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with an available E.coli antibody. This milestone is a result of the Halberd sponsored research being conducted at GreenBioAz by Dr. ...
Paves Way for Disease Elimination by Radio Frequency Waves Jackson Center, PA, March 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody’s antigen-neutralizing properties. This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease eradication methodology through ...